F-1: Biodexa Pharmaceuticals Eyes Resale of $3.9 Million in Ordinary Shares via Depositary Shares
Registration Statement
Biodexa Pharmaceuticals is registering for the resale of approximately $3.9 million worth of ordinary shares through depositary shares by existing shareholders.
Summary
- Biodexa Pharmaceuticals is registering for the resale of 1,283,541,200 ordinary shares, represented by 3,208,853 American Depositary Shares (ADSs), by selling shareholders.
- These shares consist of 373,521,200 ordinary shares (933,803 ADSs) from private placements in December 2023 and 910,020,000 ordinary shares (2,275,050 ADSs) issuable upon exercise of pre-funded warrants.
- The selling shareholders may sell these shares over time through market transactions or negotiated deals.
- Biodexa will not receive proceeds from the sale of ADSs by selling shareholders, except for minimal proceeds if pre-funded warrants are exercised for cash.
- The company's ADSs are listed on the NASDAQ Capital Market under the symbol BDRX, with a last reported closing price of $1.17 on March 15, 2024.
- Investing in Biodexa's securities involves risks, as detailed in the prospectus.
Sentiment
Score: 4
Explanation: The document focuses on a resale of shares, which is generally neutral. However, the company's need for additional financing and the risks associated with its business model contribute to a slightly negative sentiment.
Risks
- Investing in Biodexa's securities involves risks, as detailed in the prospectus.
- The company has incurred significant losses since its inception and anticipates future losses.
- Additional financing is required in the short term, raising doubts about the company's ability to continue as a going concern.
- The company's operations are in early-stage development with no recurring revenue.
- The company is exposed to political, regulatory, social, and economic risks related to the United Kingdom's exit from the European Union.
- The company's future success depends on product development and the ability to successfully license product candidates.
- The company relies on third parties for preclinical and clinical trials and manufacturing, which could lead to delays or harm the business.
- The price of the company's Depositary Shares may be volatile.
- Shareholder ownership interests in the company may be diluted as a result of future financings and/or additional acquisitions.
- As a foreign private issuer, the company is not required to comply with many of the corporate governance standards of NASDAQ applicable to companies incorporated in the United States.
Future Outlook
The company expects to continue to incur losses for the foreseeable future and will need to raise additional capital to fund operations beyond the third quarter of 2024.
Industry Context
The pharmaceutical and biotechnology industries are highly competitive, with numerous companies developing products that could compete with Biodexa's product candidates.
Stakeholder Impact
- Shareholders may experience dilution as a result of future financings.
- The company's ability to continue as a going concern depends on obtaining additional capital.
- The company's success depends on the ability to complete the development of product candidates and license them to partners.
Next Steps
- The selling shareholders may sell all or a portion of the Ordinary Shares represented by Depositary Shares from time to time in market transactions through any market on which our Depositary Shares are then traded, in negotiated transactions or otherwise, and at prices and on terms that will be determined by the then prevailing market price or at negotiated prices directly or through a broker or brokers, who may act as agent or as principal or by a combination of such methods of sale.
Key Dates
| Date | Description |
|---|---|
| 2013-11-20 | Date of License Agreement between Melior and Bukwang |
| 2023-03-27 | Effective date of one-for-20 reverse split of Ordinary Shares and ratio change of Ordinary Shares to Depositary Shares. |
| 2023-04-26 | Cancellation of admission of Ordinary Shares on AIM became effective. |
| 2023-06-14 | Date of annual general meeting of shareholders (June AGM). |
| 2023-06-14 | Date of general meeting of shareholders (June GM). |
| 2023-06-15 | Effective date of Re-Designation and Subdivision. |
| 2023-07-05 | Effective date of ratio change in the number of Ordinary Shares represented by Depositary Shares. |
| 2023-11-22 | Date of Assignment and Exchange Agreement with Adhera Therapeutics, Inc. |
| 2023-11-22 | Date of license agreement with Melior relating to the tolimidone compound. |
| 2023-12-21 | Date of closing of the transactions contemplated by each of the Assignment and Exchange Agreement and the License Agreement. |
| 2023-12-21 | Date of completion of underwritten public offering. |
| 2024-03-15 | Last reported closing price of Depositary Shares on NASDAQ Capital Market. |
| 2024 | Expected start of recruitment for Phase IIa open-label study of tolimidone in patients with T1D. |
Keywords
Biodexa Pharmaceuticals, ordinary shares, depositary shares, ADS, resale, selling shareholders, pre-funded warrants, NASDAQ, BDRX, financial risk, biopharmaceutical
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.